Add this topic to your myFT Digest for news straight to your inbox
Group of 11 pharma, tech and luxury shares echoes US dominance of ‘Magnificent Seven’
Best-selling Tagrisso drug slows progression of most common form of the disease at an early stage
Annual earnings at Anglo-Swedish pharma group miss expectations but revenues rise to $45.8bn
James Muir was discriminated against on the basis of his mental health disability
State aid package worth tens of millions of pounds expected as part of any agreement
Gracell Biotechnologies would operate as wholly owned subsidiary under terms of deal
Anglo-Swedish pharma group agrees to buy Seattle-based biotech Icosavax
Deal with Absci is the latest between big pharma and tech companies to build new disease treatments
Group plans to refocus on 30 core brands
Vaccine recipient claims he suffered side effect of severe blood clot
Anglo-Swedish drugmaker’s oncology and rare disease medication sales offset waning demand for Covid jabs
Drugmaker upbeat on full data after initial findings disappointed investors
Drugmaker says settlements will avoid costly litigation but claims are ‘without merit’
Anglo-Swedish group is latest to challenge Medicare’s new power to negotiate prices for a limited number of medicines
Drugmaker says it is working on new technologies to develop vaccines for infectious diseases where there is ‘high unmet need’
Drugmaker reports 38% jump in earnings as it expands genomic medicine business
Trial studied patients with advanced non-small cell lung cancer
Move highlights growing trend by businesses to insulate themselves from the region’s geopolitics
France is challenging a German-led plan to build up Europe’s air defences
Anglo-Swedish drugmaker views listing a separate unit in Hong Kong as potential shelter from global strife
Drugmaker seeks opportunities due to ageing population and burgeoning biotech industry
Pharma group’s shares are up more than 120 per cent in the past five years
Drugmaker’s chief executive Pascal Soriot had talks last year about a role with US group Biogen
Industry watchers say UK-listed rival AstraZeneca has a stronger pipeline and benefits from its oncology expertise
Drugmaker hails innovative biotech groups and says market is open to foreign buyers
UK Edition
